The Mosaic HIV vaccine is one of only five experimental vaccines to make it this far since the HIV/AIDS epidemic began.
Other researchers caution seeing this vaccine as the final solution to the virus. With this positive result, the experts involved in the experiment are now moving to the next phase of human trials involving 2,600 women in southern Africa who are at risk of contracting HIV.
Now published its key data on early stages, explained in the company Johnson & Johnson, whose daughter Janssen pharmaceuticals has developed a vaccine.
It is hoped the new vaccine would offer much better protection against the nearly unlimited number of HIV strains found across the world. While the monkey test is encouraging, there need to be more tests to show that the drug could effectively fend off infections in humans.
Researchers, including those from Harvard Medical School in the U.S., found that the "mosaic" vaccine, created by combining pieces of different HIV viruses, is well-tolerated and generated comparable and robust immune responses against HIV in healthy adults and rhesus monkeys.
Gulbis serves a bagel to send Alexander Zverev packing — ATP Wimbledon
The Spanish third seed said after falling in fading light: "There's nothing I can do.to say something now makes no sense". Germany's Philipp Kohlschreiber didn't have as much fortune, falling to US Open finalist Kevin Anderson 6-3, 7-5, 7-5.
The most effective combination was called the Ad26/Ad26 plus gp140 vaccine candidate - it protected two-thirds of the vaccinated monkeys against infection.
Scientists tested various combinations of the mosaic vaccine in people aged 18 to 50 who did not have HIV and were healthy.
About 37 million people worldwide live with HIV or Aids, and there are an estimated 1.8 million new cases every year. The virus is also able to mutate, thus eluding attack from the human immune system. To address these methodological issues, Barouch and colleagues evaluated the leading mosaic adenovirus serotype 26 (Ad26)-based HIV-1 vaccine candidates in parallel clinical and pre-clinical studies to identify the optimal HIV vaccine regimen to advance into clinical efficacy trials.
It has also helped to protect monkeys from the virus similar to HIV.
"Implementation of even a moderately effective HIV vaccine together with the existing HIV prevention and treatment strategies is expected to contribute greatly to the evolving HIV/AIDS response", the editorial continued.
Vaccine caused the correct reaction of the immune system all 393 participants. The adults came from clinics across East Africa, South Africa, the USA and Thailand.
Buchbinder said that she hoped "to validate our non-human primate model to see if it works for humans and if we see the same correlates of protection". They gave the monkeys the HIV-1 vaccine to protect against a simian-human immunodeficiency virus, i.e., HIV that infects monkeys.